Ontario joins the shift to biosimilars
On December 20, the Ontario government announced that it will shift from biologics to biosimilars for everyone covered by the Ontario Drug Benefit (ODB) program. By expanding the use of biosimilar drugs, Ontario is following in the footsteps of British Columbia, Alberta, New Brunswick, Quebec, Nova Scotia, and the Northwest Territories.
